Trethera Corporation

21 articles about Trethera Corporation

• National Institute of Health to Fund Preclinical Development of Trethera Lead Drug, TRE-515, for Treatment of Crohn’s Disease

  9/25/2023

  Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced today that it was awarded a Small Business Technology Transfer (STTR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) division of the National Institute of Health (NIH).

• Globally Recognized Expert in Rare Neurologic Diseases, Dr. Michael Levy, Joins Trethera Scientific Advisory Board

  9/5/2023

  Trethera Corporation announced the appointment of Michael Levy, MD, PhD, to its Scientific Advisory Board.

• Trethera Receives NIH Grant for Preclinical Development in the Pediatric Neurologic Disease Acute Disseminated Encephalomyelitis

  8/14/2023

  Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced today that it was awarded a $600,000 Small Business Technology Transfer (STTR) grant from the National Institute of Allergy and Infectious Diseases (NIAID).

• Trethera Receives Grant from National Institute of Allergy and Infectious Diseases for the Advancement of TRE-515 in Lupus

  6/27/2023

  Trethera Corporation announced that it was awarded a $0.6M Small Business Technology Transfer grant from the National Institute for Allergy and Infectious Diseases.

• Trethera Receives $2 Million National Cancer Institute Grant for Advancement of Clinically Relevant Biomarkers in Phase 1 Trial

  5/30/2023

  Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced today that it was awarded a $2 million Small Business Innovative Research (“SBIR”) grant from the National Cancer Institute (“NCI”).

• Dose Escalation Portion of Phase 1 Solid Tumors Trial Produces Favorable Results in Heavily Pretreated Solid Tumor Patients

  3/15/2023

  Trethera Corporation (“Trethera”) received a unanimous recommendation from the independent safety review committee (“SRC”) to continue clinical trial advancement of Trethera’s lead development asset, TRE-515, its first-in-class deoxycytidine kinase (“dCK”) inhibitor.

• Trethera Announces Appointment of Laurent Dubois to Board of Directors

  2/15/2023

  Trethera Corporation, a clinical-stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced the appointment of Laurent Dubois to the Trethera Board of Directors as an independent director.

• Trethera Announces Poster Presentation at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

  1/24/2023

  Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announces an upcoming poster presentation at the 8th Annual Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis.

• Trethera Announces Appointment of R. Boyd Quinnell to Board of Directors

  1/18/2023

  Trethera Corporation (“Trethera”), a clinical-stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced today the appointment of Boyd Quinnell, CPA, MBA, to the Trethera Board of Directors as an independent director.

• Trethera Receives $1.6 Million National Eye Institute Grant for Continued Advancement of TRE-515 Optic Neuritis Program

  10/19/2022

  Trethera Corporation announced that the National Eye Institute, a division of the National Institutes of Health, has awarded Trethera a $1.6 million Fast-Track STTR commercialization grant to further develop TRE-515 as a treatment for optic neuritis.

• Trethera Announces Multiple Sclerosis Treatment Poster Presentation at the American Neurological Association Annual Meeting

  10/4/2022

  Trethera Corporation announces an upcoming poster presentation at the 147th Annual Meeting of the American Neurological Association (ANA).

• Trethera and UCLA Publish Data Demonstrating TRE-515 Ability to Control and Improve Multiple Sclerosis Symptoms in Mouse Models

  9/7/2022

  Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announces the publication of new results in the peer-reviewed journal Immunology demonstrating that TRE-515 improved multiple sclerosis (MS) symptoms in mouse models.

• Trethera Announces FDA Orphan Drug Designation Granted to TRE-515 in the Treatment of Acute Disseminated Encephalomyelitis

  8/30/2022

  Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Status (ODS) to TRE-515, Trethera’s first-in-class drug for the treatment of acute disseminated encephalomyelitis (ADEM).

• Trethera Receives U.S. Patent Office Notice of Allowance Covering TRE-515 Structural Claims, Extending Protections to Late 2041

  8/17/2022

  Trethera Corporation announces that the United States Patent and Trademark Office issued a Notice of Allowance for a composition of matter patent covering the polymorphic form of TRE-515.

• Trethera Announces FDA Orphan Drug Designation Granted to TRE-515 for the Treatment of Demyelinating Optic Neuritis

  8/9/2022

  Trethera Corporation (“Trethera”), announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Status (ODS) to TRE-515 for the treatment of optic neuritis (ON).

• 

  Clinical Catch-Up: NIH's COVID-19 Trial and All About ASCO

  6/6/2022

  It was a busy, busy week for clinical trial news and updates, largely driven by the annual ASCO meeting taking place June 3-7 in Chicago.

• Trethera Phase 1 Solid Tumors Trial Dose Escalates To Fourth Cohort After Safety Review Committee Determines Primary Trial Endpoint Achieved

  6/1/2022

  Trethera Corporation (“Trethera”), announces that an independent safety review committee has unanimously recommended further trial advancement following review of the favorable results from the company’s Phase 1a dose escalation clinical trial of TRE-515, its first-in-class deoxycytidine kinase (“dCK”) inhibitor.

• Trethera Corporation announces appointment of Timothy "Tim" Donahue, M.D. to the Board of Directors

  1/31/2019

  Trethera Corporation announced the nomination and acceptance of Timothy Donahue to Trethera's Board of Directors by unanimous vote of the Board.

• Trethera Corporation and KYAN Therapeutics announce collaboration to develop artificial intelligence-driven optimization of solid cancer combination therapy

  10/25/2018

  Trethera Corporation and KYAN Therapeutics announced an agreement to collaborate on preclinical studies evaluating up to four different tumor types beginning this year leveraging their unique expertise to develop best-in-class combination therapies addressing unmet needs in solid tumors.   

• Trethera Announces FDA Clearance of Investigational New Drug Application for TRE-515

  2/5/2018

  Under this IND, Trethera plans to initiate a Phase 1 study designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of TRE-515 as well as validate several biomarkers in relapsed and/or refractory MDS patients who have no available alternative therapy.